Patrys Deoxymab 3E10 patent granted in the U.S.

Patrys’ Deoxymab 3E10 patent granted in the U.S.  First 3E10 cancer treatment patent has been granted in United States, providing protection on the technology to April 2031  Patent covers 3E10 variants, including Patrys’ lead candidate PAT-DX1, for treatment for several challenging cancers  Granting of patent triggers milestone payment of $180,000, as Patrys shares, to the vendors of Nucleus Th